ESMO - Eur. Oncology

The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.

[ESMO - Eur. Oncology @myESMO]

📢 ESMO is inviting applications for Editor-in-Chief positions for 3 new journals launching in 2026:
- ESMO Genitourinary Oncology
- ESMO Oncology Policy & Science
- ESMO Oncology & Artificial Intelligence

✅ Open to ESMO members
📅 6 September 2026
🔗https://t.co/p7jWC0Jnye

[ESMO - Eur. Oncology @myESMO]

Can #AI help streamline multidisciplinary tumour boards (#MDT)? Research found moderate-to-high concordance between AI recommendations and MDT decisions. As @rdienstmann notes, the focus now is validation and real-world impact.
➡️ https://t.co/PKuIPw8GTa

#HealthAI

[ESMO - Eur. Oncology @myESMO]

📣 Abstract submission is now OPEN for the ESMO Sarcoma and Rare Cancers Congress 2027! 4–6 March 2027 | Lugano, Switzerland

⏰ Submit by 24 November at 21:00 CET
🔗 https://t.co/2s9LuNMOge

Be part of a leading forum shaping the future of rare cancers care. #ESMORareCancers27

[ESMO - Eur. Oncology @myESMO]

Are you planning to take the #ESMOExamination? Join the upcoming #YO4YO HowTo Virtual Session with Paul Gougis and Myrto Moutafi for practical guidance on how to prepare effectively. #ESMOYOC
📅 26 August 2026, 15:00-16:00 CEST
🔗 https://t.co/96NVTllH7Q

[ESMO - Eur. Oncology @myESMO]

📣 New ESMO #ClinicalPracticeGuideline Express Update on pancreatic cancer: updated recommendations include daraxonrasib for second-line treatment of metastatic pancreatic cancer
🔗 https://t.co/S6UHUmPvGA

#ESMOGuidelines #PancreaticCancer #CancerResearch #Oncology

[Annals of Oncology @Annals_Oncology]

🆕article in press: Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304) @Prof_IanD; @ChrisSweens1
https://t.co/3nLwBNnI4m

[ESMO - Eur. Oncology @myESMO]

⏰ There are just 48 hours left to register for #MAP2026 at the late rate.
Join leading clinicians and scientists in London, 10-11 Sept, for focused discussions on the latest advances in #PrecisionOncology.

⏳ Late registration closes 19 Aug.
🔗 https://t.co/3uEdhobDue

[ESMO - Eur. Oncology @myESMO]

📣 #ESMO26: You still have time to register and benefit from advantageous fees! Join Yelena Janjigian, Scientific Committee Co-Chair, for an extraordinary gathering of leading minds in oncology from around the globe

⏰ Late registration deadline: 16 September 2026
🔗 https://t.co/GoSzYUInNN

#esmomeetings

[ESMO - Eur. Oncology @myESMO]

#ESMOGI26: Is AI in #GIOncology entering a new phase?
From pathology & imaging to surgery, advances show the growing potential of #AI in #GastrointestinalCancers. The next step is proving clinical value beyond technical performance.
#ESMODailyReporter
🔗 https://t.co/qvFIFAs7r3

[The Breast Online @TheBreastOnline]

Now out in @TheBreastOnline

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors🧬

https://t.co/mm1Ymkj1qX

[FabriceAndre @FAndreMD]

.@esmo_iotech publishes innovations in immuno-oncology. high quality papers under the leadership of @LoiSher and @HaanenJohn

[Annals of Oncology @Annals_Oncology]

🆕article in press: Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
https://t.co/pu218qQQ7J

[Sherene Loi, MD @LoiSher]

🚩Can an mRNA vaccine make “cold” tumours more responsive to immunotherapy 🌶️?

A recent @Nature study suggests mRNA vaccination may activate systemic innate immunity & potentially sensitise tumours to checkpoint blockade.

The clinical data need prospective validation, but the biological concept is compelling.

The Authors discuss the implications in an @esmo_iotech commentary. 🙏@adam_grippin @StevenLin_MDPhD

Nature article linked: https://t.co/BE5zV4EEDm
IOTECH commentary: https://t.co/wmplUX63yk

@myESMO @esmo_iotech #CancerImmunotherapy #mRNA #ImmunoOncology #ESMO #ESMOIOTECH

[ESMO - Eur. Oncology @myESMO]

🤖 #ESMOAI26: Share research that translates technology into improved patient care. Submit your abstract by 1 September.

🔗 https://t.co/gkkjEtiUGN

#esmomeetings

[Annals of Oncology @Annals_Oncology]

🆕article in press: SKYSCRAPER-03: A phase III study of tiragolumab + atezolizumab vs. durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based Concurrent chemoradiation @HwakeleeMD
https://t.co/DvggaZuCjq

[ESMO - Eur. Oncology @myESMO]

👉 New Guideline Slide Set featuring content from the recently published ESMO Metastatic Colorectal Cancer Living Guideline v2.0. This open resource is offered in condensed format (PPT), ready for your presentations

🔗 https://t.co/RHZFQC6PNn

[ESMO - Eur. Oncology @myESMO]

⏰ There is still time to register for #MAP2026.
Join the Molecular Analysis for Precision Oncology Congress, 10-11 Sept in London, for focused discussions on the latest developments in #PrecisionOncology.

Late registration closes on 19 Aug
🔗 https://t.co/l9vkpPxIxM

#esmomeetings

[ESMO - Eur. Oncology @myESMO]

📣 #ESMONovelTherapies27: Join us in Lugano for a symposium focused on the practical decisions oncologists face every day, from selecting the right treatment to preventing and managing toxicities.

View the online programme.
🔗 https://t.co/XIMS57nDxa

#esmomeetings